Boston-based KingsCrowd, a leading independent, third-party equity crowdfunding research and rating service has named Amnion Life - a revolutionary NICU medical device company, as it’s latest “Top Deal”.
Amnion Life is currently raising approximately $1 million of it’s $4 million Series A funding round through a public investment opportunity that can be found at www.wefunder.com/amnion.life.
“Amnion Life’s flagship product is the AmnioBed™, and we were impressed by what the Amnion Life founding team has been able to accomplish to date,” said Chris Lustrino, Founder and CEO of KingsCrowd. “We analyze startups across the equity crowdfunding portals and through our robust in-house due-diligence process we identify the top 10% of deals we consider to be ‘Top Deals.’ Amnion Life definitely fit the bill,” said Lustrino.
Additional information can be found at www.kingscrowd.com/a/277/top-deal- the-future-of-preterm-infant-care. Act quickly and receive the Amnion Life business plan and their insightful evaluation at no charge. Or visit Wefunder.com to learn more.
Amnion Life Founder & CEO, Dr Amir Fassihi said, "AmnioBed strives offer improved thermoregulation, hydration, and skin protection, helping to reduce complications and save lives. Potentially improving the rate of weight gain and growth. Our solution may also significantly reduce direct costs of the NICU visit by decreasing complications associated with preterm birth while improving the infants' comfort."
KingsCrowd is the leading independent, third-party unbiased ratings and analytics service for the equity crowdfunding market. Through in-depth market research and company due diligence, they provide investors with the necessary information needed to make an informed investment decision in the new online private market.
The Amnion Life name, Amnion Life logo and AmnioBed are all trademarks of Amnion Life. All rights reserved.